JNJ | Weekly | Haru Insights

The FDA approval of the OTTAVA Robotic Surgical System marks a transformative strategic milestone, positioning Johnson & Johnson as a serious competitor in the $60B+ surgical robotics market and signaling a definitive shift from a traditional pharma company to a diversified medtech innovator.
The $5.5 billion resolution of the talc baby powder litigation removes a decades-long legal overhang, delivering long-awaited clarity and enabling JNJ to focus on strategic growth initiatives without the drag of legacy liabilities.

OTTAVA’s FDA approval is a game-changing validation of JNJ’s medtech pivot, unlocking a high-margin, scalable growth engine with the potential to redefine its long-term valuation and solidify its position as a modern healthcare innovator.
The talc settlement clears the path for aggressive capital allocation, empowering JNJ to accelerate M&A, R&D, and innovation with renewed investor confidence and zero legacy distraction.
A resilient oncology portfolio anchored by Darzalex, Carvykti, and Inlexzo continues to deliver outsized growth, reinforcing JNJ’s dominance in one of the most lucrative and fast-evolving therapeutic areas.
Institutional ownership remains sky-high with negligible short interest, reflecting deep conviction in JNJ’s diversified model, defensive cash flow, and long-term growth trajectory.
Leadership continuity under Tom Cavanaugh, backed by strong R&D partnerships, signals sustained innovation momentum and confidence in executing the company’s transformation beyond legacy franchises.

Johnson & Johnson (JNJ)[Tv]